Search Results - "Mogil'naia, V I"

Direct switch from conventional levodopa to stalevo (levodopa/carbidopa/entacapone) improves quality of life in Parkinson's disease: results of an open-label clinical study by Litvinenko, I V, Odinak, M M, Mogil'naia, V I, Sologub, O S, Sakharovskaia, A A

“…The most effective symptomatic treatment for Parkinson's disease (PD) is levodopa/dopa decarboxylase (DDC)-inhibitor or conventional levodopa. However, after a…”
Get more information

Pain and depression in Parkinson's disease: new therapeutic possibilities of pramipexole by Letvinenko, I V, Odinak, M M, Mogil'naia, V I

“…An aim of a study was to establish the relationship between pain, motor complications and depression in Parkinson's disease and evaluate an effect of the 3…”
Get more information

Memantine (akatinol) therapy of cognitive impairment in Parkinson's disease complicated by dementia by Litvinenko, I V, Odinak, M M, Mogil'naia, V I, Perstenev, S V

“…The study has investigated the effect of NMDA-glutamate receptor antagonist memantine in the 52-weeks therapy of 32 PD patients with dementia (PDD) compared…”
Get more information

Efficacy and safety of galantamine (reminyl) in the treatment of dementia in patients with Parkinson's disease (open-label controlled trial) by Litvinenko, I V, Odinak, M M, Mogil'naia, V I, Emelin, A Iu

“…Forty-one Parkinson's disease patients with dementia (21 galantamine group, 20--control group) with onset of dementia at least two years after the…”
Get more information